Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01555892 |
|
Recruitment Status :
Recruiting
First Posted : March 16, 2012
Last Update Posted : June 30, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Subjects have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease or severe chronic active Epstein Barr Virus (CAEBV) which has come back, is at risk of coming back, or has not gone away after treatment, including the best treatment we know for these diseases.
Some of these patients show signs of virus that is called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever ("mono" or the "kissing disease") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with HD and NHL, suggesting that it may play a role in causing Lymphoma. The cancer cells and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction. We want to see if special white blood cells, called GRALE T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor.
We have used this sort of therapy to treat a different type of cancer called post transplant lymphoma. In this type of cancer the tumor cells have 9 proteins made by EBV on their surface. We grew T cells in the lab that recognized all 9 proteins and were able to successfully prevent and treat post transplant lymphoma. However, in HD and NHL, T/NK-lymphoproliferative disease, and CAEBV, the tumor cells and B cells only express 4 EBV proteins. In a previous study, we made T cells that recognized all 9 proteins and gave them to patients with HD. Some patients had a partial response to this therapy but no patients had a complete response. We then did follow up studies where we made T cells that recognized the 2 EBV proteins seen in patients with lymphoma, T/NK-lymphoproliferative disease and CAEBV. We have treated over 50 people on those studies. About 60% of those patients who had disease at the time they got the cells had responses including some patients with complete responses. This study will expand on those results and we will try and make the T cells in the lab in a simpler faster way. These cells are called GRALE T cells. These GRALE T cells are an investigational product not approved by the FDA.
The purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique. We will learn what the side effects are and to see whether this therapy might help patients with HD or NHL or EBV associated T/NK-lymphoproliferative disease or CAEBV.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hodgkin's Disease Non-Hodgkin's Lymphoma Lymphoproliferative Disease Lymphoma | Biological: EBV-specific T cells: A Biological: EBV-specific T cells: B | Phase 1 |
Subjects (or their syngeneic donor) will give blood for investigators to make EBV-specific (GRALE) T cells in the lab. These cells will be grown and frozen for the subject.
The GRALE T cells will then be thawed and injected into the subject over 1-10 minutes. Initially, two doses of GRALE T cells will be given 2 weeks apart.
If after the 2nd infusion there is a reduction in the size of the lymphoma on CT or MRI scan as assessed by a radiologist, the subject can receive additional doses of the GRALE T cells if they wish (up to 6 times). Follow up testing will be collected just like after the 1st infusion.
All of the treatments will be given by the Center for Cell and Gene Therapy at Texas Children's Hospital or Houston Methodist Hospital.
We will follow the subjects after the injections. They will either be seen in the clinic or the subject will be contacted by a research nurse yearly for 5 years.
If they receive additional doses of the GRALE T cells as described above, they will be followed until 5 years after the last dose of GRALE T-cells.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 136 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma |
| Actual Study Start Date : | January 14, 2013 |
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | July 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: EBV-specific T cells: A
Group A: Patients in second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiple relapsed patients in remission who are at a high risk of relapse)** or any patient with primary disease or in first or subsequent remission if immunosuppressive chemotherapy is contraindicated. Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule: Day 0: 1 x 10^8 cells/m2 Day 14: 2 x 10^8 cells/m2 ** Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant. |
Biological: EBV-specific T cells: A
Dose Level 3: 1 x 10^8 cells/m2 + 2 x 10^8 cells/m2
Other Name: LMP, BARF1 and EBNA1 specific CTLs |
|
Experimental: EBV-specific T cells: B
Group B: Patients in remission or with minimal residual disease (MRD) status after autologous or syngeneic SCT. Patients will be treated at Dose Level 3. Each patient will receive 2 injections, 14 days apart, according to the following dosing schedule: Day 0: 1 x 10^8 cells/m2 Day 14: 2 x 10^8 cells/m2 |
Biological: EBV-specific T cells: B
Dose Level 3: 1 x 10^8 cells/m2 + 2 x 10^8 cells/m2 |
- Assessment of toxicity of escalating doses of LMP, BARF1 and EBNA1 T lymphocytes [ Time Frame: 8 weeks ]To determine the safety of escalating doses of 2 intravenous injections of autologous or syngeneic rapid LMP, BARF1 and EBNA1 specific T-lymphocytes (VSTs) in patients with EBV-associated Hodgkin's Disease or non-Hodgkin's lymphoma or T/NK-lymphoproliferative disease and CAEBV.
- Determine survival and immune function of LMP/BARF1/EBNA1-specific cytotoxic T-lymphocyte lines [ Time Frame: 1 year ]To determine the survival and the immune function of LMP/BARF1/EBNA1-specific cytotoxic T-lymphocyte lines
- Assess anti-viral and anti-tumor effects of LMP/BARF1/EBNA1-specific EBVST [ Time Frame: 1 year ]To assess the anti-viral and anti-tumor effects of LMP/BARF1/EBNA1-specific EBVST
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria at time of Procurement
- Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)-T/NK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV) who may subsequently be eligible for the treatment component
- EBV positive tumor (can be pending at this time)
- Weighs at least 12kg
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Inclusion Criteria at time of Infusion
-
Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non-Hodgkin's Lymphoma (regardless of histologic subtype), or EBV (associated)-T/NK-lymphoproliferative disease or Severe Chronic Active EBV (CAEBV)* and
In second or subsequent relapse (or first relapse or with active disease if immunosuppressive chemotherapy contraindicated or multiply relapsed patients in remission who have a high risk of relapse)** OR any patient with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a Richter's transformation of CLL. (Group A)
OR
In remission or with minimal residual disease status after autologous or syngeneic SCT. (Group B)
- EBV positive tumor
- Patients with life expectancy greater than or equal 6 weeks.
- Patients with bilirubin less than or equal to 3x upper limit of normal, AST less than or equal 5x upper limit of normal, and hemoglobin greater than or equal to 7.0 (may be a transfused value).
- Patients with a creatinine less than or equal to 2x upper limit of normal for age
- Pulse oximetry of > 90% on room air
- Patients should have been off other investigational therapy for 4 weeks prior to entry in this study. PD1/PDL inhibitors will be allowed if medically indicated.
- Patients with a Karnofsky/Lansky score of greater than or equal to 50
- Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
-
Informed consent explained to, understood and signed by patient/guardian. Patient/guardian given copy of informed consent.
-
CAEBV is defined as patients with high EBV viral load in plasma or PBMC (> 4000 genomes per ug PBMC DNA) and/or biopsy tissue positive for EBV
- Patients with relapsed or refractory lymphoma that are eligible for a stem cell transplant will not be treated on this study as an alternative to transplant.
-
Exclusion Criteria at Time of Procurement
1. Active infection with HIV, HTLV, HBV, HCV (can be pending at this time)
Exclusion Criteria at Time of Infusion
- Pregnant or lactating
- Severe intercurrent infection.
- Current use of systemic corticosteroids > 0.5 mg/kg/day
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01555892
| Contact: Helen E Heslop, MD | 832-824-4662 | hheslop@bcm.edu | |
| Contact: Vicky Torrano | 832-824-7821 | vxtorran@txch.org |
| United States, Texas | |
| Houston Methodist Hospital | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Helen E Heslop, MD 832-824-4662 hheslop@bcm.edu | |
| Contact: Vicky Torrano 832-824-7821 vxtorran@txch.org | |
| Texas Children's Hospital | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Helen E Heslop, MD 832-824-4662 hheslop@bcm.edu | |
| Contact: Vicky Torrano 832-824-7821 vxtorran@txch.org | |
| Principal Investigator: | Helen E Heslop, MD | Baylor College of Medicine |
| Responsible Party: | Helen Heslop, Professor, Baylor College of Medicine |
| ClinicalTrials.gov Identifier: | NCT01555892 |
| Other Study ID Numbers: |
H-29617-GRALE GRALE ( Other Identifier: BCM/CAGT ) P50CA126752 ( U.S. NIH Grant/Contract ) |
| First Posted: | March 16, 2012 Key Record Dates |
| Last Update Posted: | June 30, 2022 |
| Last Verified: | June 2022 |
|
EBV Hodgkin's Lymphoma Non-Hodgkin's Lymphoma Lymphoma Relapse Autologous or Syngeneic Stem Cell Transplant |
T/NK-lymphoproliferative disease LMP BARF1 EBNA1 |
|
Lymphoma Lymphoma, Non-Hodgkin Hodgkin Disease Lymphoproliferative Disorders Neoplasms by Histologic Type |
Neoplasms Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |